Savara is transitioning from a single-asset biotech to a rare disease commercial infrastructure. Click here to read more on ...
Integrated SWIFT-1/2 enrolled 762 patients with type 2 asthma; depemokimab 100 mg SC q26 weeks achieved clinically meaningful exacerbation reductions versus placebo. Comorbid CRSwNP predicted greater ...
Dr Aaron Holley argues that skeletal muscle — not just heart and lungs — is a key, often missed driver of activity intolerance, and may hold the answer to unexplained dyspnea.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results